Positive Early Results For Addex Parkinson’s Drug Dipraglurant Spur Hopes For Deal
This article was originally published in Pharmaceutical Approvals Monthly
In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa. If future trials are positive, the drug would have a significant positive impact on Parkinson’s patients, says the Michael J. Fox Foundation.